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Passive immunisationPrevious studies show that a recombinant modiﬁed vaccinia Ankara (MVA) virus expressing VP2 of AHSV
serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha
receptor gene knock-out mice (IFNAR /) against challenge. Follow up experiments indicated that pas-
sive transfer of antiserum, from MVA-VP2 immune donors to recipient mice 1 h before challenge, con-
ferred complete clinical protection and signiﬁcantly reduced viraemia.
These studies have been extended to determine the protective effect of MVA-VP2 vaccine-induced anti-
serum, when administered 48 h before, or 48 h after challenge. In addition, passive transfer of spleno-
cytes was undertaken to assess if they confer any degree of immunity to immunologically naïve
recipient mice. Thus, antisera and splenocytes were collected from groups of mice that had been vacci-
nated with MVA-VP2, or wild type MVA (MVA-wt), for passive immunisation of recipient mice. The latter
were subsequently challenged with AHSV-4 (together with appropriate vaccinated or unvaccinated con-
trol animals) and protection was assessed by comparing clinical signs, lethality and viraemia between
treated and control groups. All antiserum recipients showed high protection against disease (100% sur-
vival rates even in mice that were immunised 48 h after challenge) and statistically signiﬁcant reduction
or viraemia in comparison with the control groups. The mouse group receiving splenocytes from MVA-
VP2 vaccinates, showed only a 40% survival rate, with a small reduction in viraemia, compared to those
mice that had received splenocytes from MVA-wt vaccinates. These results conﬁrm the primarily
humoral nature of protective immunity conferred by MVA-VP2 vaccination and show the potential of
administering MVA-VP2 speciﬁc antiserum as an emergency treatment for AHSV.
 2015 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
African horse sickness (AHS) is an arthropod-borne viral disease
of solipeds transmitted by haematophagous insects of the genus
Culicoides, the horse being the most severely affected species. Mor-
tality rates of AHSV outbreaks in immunologically naïve popula-
tions may exceed 90% (Mellor and Hamblin, 2004).
All of the different isolates, strains and serotypes of African
horse sickness virus (AHSV) are classiﬁed within the species African
horse sickness virus, genus Orbivirus, family Reoviridae. AHSV is clo-
sely related to bluetongue virus, which causes bluetongue diseasein ruminants. The orbiviruses are characterised by a genome com-
posed of ten linear segments of dsRNA, with one copy of each of the
ten segments packaged within each virus particle. The spherical,
non-enveloped capsid of AHSV is approximately 70 nm in diame-
ter, is composed of three concentric protein layers (Roy et al.,
1994). The outer-capsid layer is formed by two major structural
proteins, VP2 and VP5 (encoded by genome-segments 2 and 6
respectively), and is primarily involved in cell attachment and cell
entry. VP2 is the most variable antigen of AHSV and is responsible
for serotype deﬁnition (Burrage et al., 1993).
AHSV infection in horses most often results in severe clinical
disease and death, although animals that do survive, exhibit a
solid, life-long but serotype-speciﬁc immunity. The humoral nat-
ure of AHS immunity has been associated with virus neutralising
antibodies (VNAb) in both horses and mice using colostrum and
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1988; Burrage et al., 1993; Crafford et al., 2013). The main target
of VNAb is AHSV VP2 (Burrage et al., 1993) and several studies
have mapped neutralising epitopes to the amino terminal half of
the VP2 protein (Bentley et al., 2000; Martinez-Torrecuadrada
and Casal, 1995; Martinez-Torrecuadrada et al., 2001).
Although less important in this respect than VP2, AHSV-VP5
appears to be both directly involved in the formation of virus neu-
tralising epitopes and indirectly involved by inﬂuencing the con-
formation of VP2 (Martinez-Torrecuadrada and Casal, 1995;
Martinez-Torrecuadrada et al., 1996). Unsurprisingly, experimen-
tal vaccines based on the outer-capsid proteins VP2 and/or VP5,
were successful (Castillo-Olivares et al., 2011; Chiam et al., 2009;
Romito et al., 1999; Roy and Sutton, 1998; Scanlen et al., 2002;
Stone-Marschat et al., 1996).
Recently, cell-mediated immune responses have been detected
in horses following inoculation with live attenuated AHSV vaccines
(Pretorius et al., 2012), or recombinant Canarypox virus expressing
AHSV VP2 and VP5 (El Garch et al., 2012). More recently, cell-med-
iated immune responses have also been observed in interferon
alpha receptor gene knock-out mice (IFNAR /) after vaccination
with single MVA recombinant viruses expressing AHSV VP2 or NS1
(de la Poza et al., 2013). Since cellular immunity has been associ-
ated with protection against BTV, it is generally assumed that the
same applies to AHSV.
After showing that MVA expressing AHSV VP2 (MVA-VP2) was
protective against AHSV infection in mice (Castillo-Olivares et al.,
2011) and horses (Alberca et al., 2014), the mechanisms of immu-
nity underlying the protective effect of MVA-VP2 vaccination were
investigated. Passive transfer of AHSV neutralising antiserum, from
MVA-VP2 vaccinated mice to immunologically naïve recipients,
was shown to be highly protective against a lethal AHSV challenge
(Calvo-Pinilla et al., 2014).
In this paper, follow-up studies investigating the relative contri-
bution of humoral and cell-mediated immunity to the protection
conferred by MVA-VP2 vaccination, using passive immunisation
of naïve recipient IFNAR / mice with splenocytes or antiserum
from MVA-VP2 vaccinated mice, are described.2. Materials and methods
2.1. Viruses and cells
Chicken embryo ﬁbroblast (DF-1) (ATCC, Cat. No. CRL-12203)
and Vero cells (ATCC, Cat. No. CCL-81) were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 2 mM glu-
tamine, penicillin (100 units/ml), streptomycin (100 lg/ml) and
10% foetal calf serum (FCS). AHSV-4 (Madrid/87) (AHSV-4) was
grown in Vero cells and MVA viruses grown in DF-1 cells. Virus
stocks were generated by infection of conﬂuent cells using a mul-
tiplicity of infection (MOI) of 0.1. At 48 h post-infection, or when a
total cytopathic effect (CPE) was visible, the cells and supernatants
were harvested and centrifuged. The virus was released from the
cells by three freeze and thaw cycles and then titrated by plaque
assay. The MVA-VP2 virus used in this study has been previously
described (Chiam et al., 2009).Table 1
Vaccination and preparation of splenocytes and antiserum donors.
Groups Day 0 Day 21
1a (5 mice) MVA-VP2 107 pfu/mouse MVA-VP2 107 pfu/mouse
1b (5 mice) MVA-VP2 107 pfu/mouse MVA-VP2 107 pfu/mouse
2 (5 mice) MVA-wt 107 pfu/mouse MVA-wt 107 pfu/mouse2.2. Mice
IFN a/b Ro/o IFNAR /mice on an A129 background were pur-
chased from B&K Universal Ltd (UK). Eight-week old mice were
used throughout. Mice were maintained under pathogen-free con-
ditions and allowed to acclimatise to the biosafety level 3 (BSL3)
animal facilities at the Centro de Investigacion en Sanidad Animal,
INIA, Madrid (INIA-CISA), for 1 week before use. All experiments
with live animals were performed under the guidelines of the
European Community (86/609) and were approved by the ethical
review committee of INIA-CISA (CEEA 2010-034).
2.3. Murine immunisations with MVA-VP2 and MVA-wt and
preparation of donor antisera and splenocytes
Groups of mice were vaccinated (107 pfu/mouse) with either
MVA-VP2 (Group 1a and Group 1b) or MVA-wt (Group 2) and used
as donors of serum and splenocytes as shown in Table 1. A third
dose was given on day 35 to 5 mice from Group 1a (mouse 1.6–
mouse 1.10). Mice from Group 1b and Group 2 were euthanised
on day 35. Mice from Group 1a were euthanized on day 50. Spleno-
cytes and blood samples were collected at termination and subse-
quently used for passive immunisation. The blood was used to
prepare donor antisera.
2.4. Adoptive transfer of splenocytes
Pools of spleen cells, obtained from mice from Group 1b (MVA-
VP2) and Group 2 (MVA-wt), were transferred via intravenous
injection (2  107 cells/mouse) to immunologically naïve recipi-
ents Groups 3 and 4 (Table 2a). Transfers were performed 24 h
before infection with AHSV-4 (106 pfu/mouse).
2.5. Passive immunisation with donor antiserum
Donor antisera S1a, S1b and S2 were prepared by pooling indi-
vidual serum samples from Groups 1a, 1b and 2 respectively
(Table 2b). The donor antisera were inactivated (30 min at 56 C)
and used for intra-peritoneal injection of 4 Groups of 10-week-
old recipient IFNAR /mice: (a) Group 5, received 400 ll of undi-
luted S1a antiserum administered 1 h before challenge; (b) Group
6 received 100 ll of diluted S1b antiserum, administered 1 h
before challenge; (c) Group 7 received 100 ll of S1b 48 h before
challenge and (d) Group 8 received 100 ll of S1b antiserum 48
after challenge.
Passively immunised mice were challenged with 106 pfu of
AHSV-4 administered subcutaneously. MVA-wt (Group 9) and
MVA-VP2 (Group 10) vaccinated control mice were infected at
the same time as the recipients. Clinical signs and viraemia were
evaluated in all the animals following challenge.
2.6. Evaluation of clinical signs after challenge with AHSV-4
Following challenge, animals were monitored twice daily and
more regularly (at least three times per day) at the onset of any
signs of morbidity, including: changes in behaviour and activity,Day 35 Day 50
MVA-VP2 107 pfu/mouse Collection of serum (S1a)
Collection of serum (S1b) and spleen (L1)
Collection of serum (S2) and spleen (L2)
Table 2
Passive immunisation and AHSV challenge.
Groups Treatment Volume and VNAb titre of Serum Challenge AHSV-4
(a) Splenocyte transfer and challenge
Group 3 Transferred with splenocytes from Group 1b (MVA-VP2 vaccinates) 24 h before challenge 2  107 cells/mouse 106 pfu/mouse
Group 4 Transferred with splenocytes from Group 2 (MVA-wt vaccinates) 24 h before challenge 2  107 cells/mouse 106 pfu/mouse
(b) Serum transfer and challenge
Group 5 Transferred with serum from MVA-VP2 vaccinates (day 0) 1 h before challenge 400 ll S1a
2.25
106 pfu/mouse
Group 6 Transferred with serum from MVA-VP2 vaccinates (day 0) 1 h before challenge 100 ll S1b
1.95
106 pfu/mouse
Group 7 Transferred with serum from MVA-VP2 vaccinates (day 2) 48 h before challenge 100 ll S1b
1.95
106 pfu/mouse
Group 8 Transferred with serum from MVA-VP2 vaccinates (day +2) 48 h after challenge 100 ll S1b
1.95
106 pfu/mouse
Group 9 Vaccinated twice with MVA-wt 107 pfu per mouse 21 and 14 days before challenge N/A⁄ 106 pfu/mouse
Group 10 Vaccinated twice with MVA-VP2 107 pfu per mouse 21 and 14 days before challenge N/A 106 pfu/mouse
* N/A: not applicable.
Table 3
Daily clinical score.
Possible clinical signs
of AHS infection in mice
Possible score values per clinical sign
0 1 2
Rufﬂed hair/pilo-erection Absent Present –
Separation from the Group Absent Present –
Reduced activity Absent Present Frequent
Ocular watery discharge Absent Present –
Nasal watery discharge Absent Present –
Abnormal respiratory rate Absent Present –
Weight loss Absent Present >10% body weight
Dehydration Absent Present –
Periorbital swelling Absent Present Compromising vision
Tremors Absent Present –
Ataxia Absent Present –
Paralysis or paresis Absent Present –
Circling gate Absent Present –
Hunching Absent Present –
Daily score (sum)
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ance, body weight loss, presence of ocular signs (conjunctivitis,
ocular discharge, swelling), changes in hydration and presence of
neurological signs (i.e. paresis, paralysis, ataxia). The humane
end-points for euthanasia included: persistent hunching, severe
conjunctivitis, signs of dehydration, loss of more than 20% of body
weight, presence of any neurological signs, or any other condition
that prevented food or water intake. Animals that displayed any of
these clinical signs were humanely euthanised by cervical disloca-
tion following anaesthesia with 5% isoﬂurane.
A clinical scoring system was used (Table 3) whereby each ani-
mal received a clinical score value per day. The value used for anal-
ysis was the individual mean clinical score for the study period
(sum of daily scores of each animal/number of days).2.7. Virus neutralisation test and VP2-speciﬁc ELISA
Determination of VNAb titres of serum samples was carried out
as described previously (Calvo-Pinilla et al., 2014). Brieﬂy, twofold
serial dilutions of serum samples were incubated with 100 TCID50
of AHSV-4 for 1 h and then overnight at 4 C. The following day,
2  104 Vero cells were added to each well and incubated for
3 days at 37 C, 5% CO2. The end-point of the assay was the highest
dilution that prevented AHSV cytopathic effect in 50% of the wells.
Antibody titres were then calculated according to Karber (1931).
Antibody levels of VP2-speciﬁc antibodies in serum were deter-
mined as previously described (Calvo-Pinilla et al., 2014).2.8. Detection of AHSV-4 in blood
Whole blood from animals was collected in EDTA at regular
intervals after challenge. Volumes of 50 ll of blood were washed
in PBS, mixed with 400 ll of water to lyse the cells and then
50 ll of 10 PBS was added to the sample. Infectious virus was
measured by standard plaque assay on Vero cells.
2.9. ELISpot assay for the detection of IFN-c producing cells
Spleens were homogenised and then ﬁltered through 70 lm cell
strainers. Erythrocytes were lysed with NH4Cl and the remaining
cells were re-suspended in RPMI media. AHSV-speciﬁc IFN-c pro-
ducing cells were measured by ELISpot assay as described previ-
ously (Calvo-Pinilla et al., 2009). Splenocytes were stimulated for
24 h with either AHSV-4 cell extract that had been inactivated by
30 min exposure to ultraviolet light (400 J/cm2) or with afﬁnity
puriﬁed AHSV-4 VP2 expressed from recombinant baculovirus
(Chiam et al., 2009). PHA (Phytohemagglutinin, 5 lg/ml) stimu-
lated control cells used as positive control and uninfected cell
extract stimulated cells were used as the negative control. The spot
count of antigen-speciﬁc cells was calculated as the spot count dif-
ference between AHSV4-stimulated cells and non-stimulated cells.
2.10. Statistical methods
Unless otherwise stated, the methods used were the same for
the splenocyte and serum transfer experiments.
Virus neutralising titre (VNT) in donor mice: titres in MVA VP2-
vaccinated and MVA-wt vaccinated mice (splenocyte transfer) and
in mice vaccinated twice or three times with MVA-VP2 (serum
transfer) were compared using Wilcoxon rank-sum tests.
Elispot data for donor mice: the numbers of cells excreting IFNc
were compared using a Kruskal–Wallis test, with mice grouped
according to vaccination status (MVA-VP2 or MVA-wt) and stimu-
lus (AHSV or VP2) (i.e. there are four groups in total). Differences
between groups were then explored using post hoc Wilcoxon
rank-sum tests.
Clinical scores in recipient mice: clinical scores in different
groups of mice were compared using a Wilcoxon rank-sum test
(splenocyte transfer) or a Kruskal–Wallis test (serum transfer). In
the latter case, differences between groups were then explored
using post hoc Wilcoxon rank-sum tests.
Viraemia in recipient mice: differences in viraemia amongst
groups of mice were assessed using linear mixed models with
log10 pfu as the response variable, days post infection (as a factor)
and group as ﬁxed effects and mouse as a random effect. Model
30 E. Calvo-Pinilla et al. / Antiviral Research 116 (2015) 27–33selection proceeded by stepwise deletion of non-signiﬁcant terms
(as judged by the Akaike information criterion) starting from a
model including days post infection and group as main effects.
Survival in recipient mice: survival in different groups of mice
were compared using log-rank tests.
VNT in recipient mice: titres at experiment end point (either
death or 14 days post infection) were analysed using a one-way
analysis of variance, followed by post hoc Tukey tests to identify
differences between groups.
A signiﬁcance level of P = 0.05 was used in all analyses. All
methods were implemented in R version 3.1.0 (R Core Team 2014).Fig. 1. AHSV speciﬁc IFN-c secreting cells measured by ELISpot assay. At 35 days
post vaccination splenocytes from MVA-VP2 and MVA-wt immunized mice were
stimulated with UV inactivated AHSV-4, baculovirus expressed AHSV-4 VP2 protein
or negative cell extracts for 24 h. Bars represent the number of IFNA-g producing
cells in samples stimulated with AHSV or VP2 after subtraction of values from cell
extract stimulated samples.
Fig. 2. Viraemia of splenocyte recipients following AHSV challenge. Virus titres,
expressed as pfu/ml of blood, were measured in mice from Group 3 (recipients of
splenocytes from MVA-VP2 vaccinates) and Group 4 (recipients of splenocytes from
MVA-wt vaccinates). Blood samples were collected on days 4, 6, 8, 11 and 14 after
challenge except for mice that died on days 3 and 7. Data are shown as mean ± STD.3. Results
It has recently been demonstrated that immunologically naïve
mice can be protected against challenge with a virulent strain of
AHSV-4, by administering serum from mice previously vaccinated
with MVA-VP2). This suggests that the protection afforded by
MVA-VP2 vaccination is mediated mainly by antibodies (Calvo-
Pinilla et al., 2014). However, it was shown in that study that
MVA-VP2 vaccination also induced a CD8+ T-cell response. These
studies have been extended to determine: (a) whether adoptive
transfer of splenocytes from MVA-VP2 vaccinates could protect
against AHSV-4 infection; and (b) whether protection by passive
immunisation with antibodies from MVA-VP2 vaccinated mice
could be observed when administered 48 h before, or 48 h after
the challenge.
3.1. Immune responses in antiserum and splenocytes donors following
MVA-VP2 and MVA-wt vaccination
Serum and splenocytes were obtained from mice that had been
vaccinated with MVA-VP2 or MVA-wt, as indicated in Section 2.
Consistent with previous ﬁndings (Calvo-Pinilla et al., 2013;
Castillo-Olivares et al., 2011), the mice did not show any signs of
infection following MVA-VP2 vaccination and developed an
AHSV-VP2-speciﬁc VNAb response. Titres at day 35 (following
two vaccinations) ranged between 1.95 and 2.15 (average 2.02)
and these were subsequently boosted on day 45 (average titre
2.25). AHSV-VP2-speciﬁc antibodies in MVA-VP2 vaccinates were
also detected by ELISA on days 35 (mean OD value 3.17; SD 0.28)
and 45 (mean OD value 3.48; SD 0.15). Antisera collected on days
35 and 50 were used for passive immunisation.
Adoptive transfer of splenocytes was carried out using spleens
harvested from MVA-VP2 and MVA-wt vaccinates collected on
day 35. Results of IFN-c ELISpot assays (Fig. 1) conﬁrmed that
the splenocytes from MVA-VP2 vaccinated donors (mice 1.1–1.5)
were functional and secreted IFN-c, with the frequency of respon-
der cells being signiﬁcantly higher than in the MVA-wt vaccinates
(mice 2.1–2.3) regardless of whether they were stimulated with
AHSV or VP2. Samples from mice 2.4 and 2.5 could not be used
in this assay.
3.2. Adoptive transfer of splenocytes and protection against AHSV
Once donor splenocytes were conﬁrmed as viable and func-
tional in the IFN-c ELIspot assay, they were transferred to groups
of 5 recipient mice, which were subsequently challenged with
AHSV-4 to assess the protective capacity of the cell-mediated
immunity.
All mice from Group 4 (receiving splenocytes fromMVA-wt vac-
cinates) and three from Group 3 (receiving MVA-VP2 splenocytes)
succumbed to the infection (Table 3), and AHSV was detected in
the blood of all mice in these groups (Fig. 2). The survival rates
(40%) and viraemia levels of Group 3 did not differ signiﬁcantly(P > 0.05) from those of Group 4. However, a reduction of clinical
score values in Group 3 relative to Group 4 was statistically signif-
icant (P = 0.008). Altogether, these data indicate that cell mediated
immunity does not play a critical role in the high level of protec-
tion that was afforded against the homologous serotype by MVA-
VP2 vaccination (see Table 4).3.3. Passive immunisation with MVA-VP2 antiserum
In this study, the inﬂuence of the time of administration and
dose of MVA-VP2-speciﬁc antiserum in protection against AHSV
was evaluated. Thus, two groups of mice were passively immun-
ised, as indicated in Section 2, and were subsequently infected
with AHSV-4, together with two vaccinated groups. As expected,
the mice that were vaccinated with MVA-wt (Group 9) developed
clinical signs typical of AHS in the IFNAR / mouse model
(Table 5). These started on day 3 post-infection and reached the
humane end-point between days 5 and 10 post-challenge. All mice
from this group were euthanised. In contrast, mice from all other
groups survived the challenge and developed, at most, very mild
clinical signs. Survival was signiﬁcantly (P < 0.001) lower for mice
in Group 9 compared with all other Groups. The clinical scores
were also signiﬁcantly higher (P < 0.001) in Group 9 compared
Table 4
Adoptive transfer of splenocytes and AHSV-4 challenge: survival and clinical score.
Groups Splenocyte
transfer
Animal ID
number
Survival Clinical
score
3 (5 mice) Splenocytes from
MVA-VP2 vaccinates
3.1 No 2.50
3.2 No 3.00
3.3 Yes 0.71
3.4 Yes 0.75
3.5 No 2.50
4 (5 mice) Splenocytes from
MVA-wt vaccinates
4.1 No 3.69
4.2 No 3.75
4.3 No 3.67
4.4 No 3.33
4.5 No 3.57
Table 5
Clinical scores and survival rates of mice following immunisation (passive or active)
and AHSV-4 challenge.
Groups Treatment Animal ID
number
Survival Clinical
score
Group
5
Transferred with serum from
MVA-VP2 vaccinates 400 ll 1 h
before challenge
5.1 Yes 0.00
5.2 Yes 0.00
5.3 Yes 0.00
5.4 Yes 0.00
5.5 Yes 0.00
Group
6
Transferred with serum from
MVA-VP2 vaccinates 100 ll 1 h
before challenge
6.1 Yes 0.20
6.2 Yes 0.40
6.3 Yes 0.00
6.4 Yes 0.00
6.5 Yes 0.00
Group
7
Transferred with serum from
MVA-VP2 vaccinates 100 ll 48 h
before challenge
7.1 Yes 0.00
7.2 Yes 0.10
7.3 Yes 0.00
7.4 Yes 0.00
7.5 Yes 0.10
Group
8
Transferred with serum from
MVA-VP2 vaccinates 100 ll 48 h
after challenge
8.1 Yes 0.20
8.2 Yes 0.60
8.3 Yes 0.10
8.4 Yes 0.10
8.5 Yes 0.30
Group
9
Vaccinated twice with MVA-wt
107 pfu per mouse 21 and
14 days before challenge
9.1 No 3.33
9.2 No 3.50
9.3 No 3.86
9.4 No 3.20
9.5 No 3.86
Group
10
Vaccinated twice with MVA-VP2
107 pfu per mouse 21 and
14 days before challenge
10.1 Yes 0.00
10.2 Yes 0.00
10.3 Yes 0.00
10.4 Yes 0.00
10.5 Yes 0.00
Fig. 3. Viraemia of antiserum recipients following AHSV challenge. Mean virus
titres, expressed as pfu/ml of blood, were measured on days 3, 5, 7 and 10 from
mice from Groups 5–10. Data are shown as mean ± STD.
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5, 7 and 10.
Differences in viraemia levels were also signiﬁcant (P < 0.05),
being highest in Group 9 relative to all other Groups, but also evi-
dent in Group 8 relative to Groups 5 and 10 (Fig. 3). Thus, the levels
of protection from the serum transfer experiment can be ranked in
the following order: Group 10 > Group 5 > Group 6 = Group
7 > Group 8 > Group 9. These data collectively indicate that transfer
of antiserum was protective when given in a time window of plus
or minus 48 h around the time of challenge. This protection is
deﬁned by a complete prevention of lethality of AHSV infection,
a signiﬁcant reduction of clinical signs and a signiﬁcant reduction
of viraemia for every sampling point. Protection was maximum
when the dose was increased (Group 5, 400 ll/mouse) and when
the administration was performed prior to virus challenge (Group
7, serum transferred 48 h before challenge). As expected the
administration of the antiserum 48 h after challenge (Group 8)was less protective than in Groups 5, 6 and 7, but even in these
conditions the affected mice recovered and clinical signs had com-
pletely disappeared by day 10 post-infection.4. Discussion
Despite the inability of MVA to replicate in most mammalian
cells in vitro and in vivo, even in immunocompromised individuals
(Gilbert, 2013; Gomez et al., 2008) recombinant MVA vaccines can
express foreign antigens in host cells upon inoculation and induce
immune responses speciﬁc for the foreign antigen. MVA vector
vaccines for viral infections have proven to be effective against a
wide range of viral diseases (Gilbert, 2013), such as Chikungunya
(Garcia-Arriaza et al., 2014) or severe acute respiratory syndrome
(Chen et al., 2005). Humoral and cellular immune responses elic-
ited against a foreign MVA-encoded antigen are higher than those
triggered with the vaccinia Western Reverse strain, in part due to
the higher levels of expression of the foreign antigen by MVA
(Ramirez et al., 2000). Moreover, MVA is able to elicit strong, spe-
ciﬁc responses under conditions of pre-existing immunity to the
vector (Ramirez et al., 2000), as seen in previous studies using
MVA in both prime and boost immunisations.
The use of MVA based vaccines, in heterologous prime-boost
vaccination regimes, is most often pursued for diseases where
cell-mediated immunity deﬁnitely plays an important role in pro-
tection, as in the case of Plasmodium falciparum (Ogwang et al.,
2013), HIV (Gomez et al. 2012; Cosma et al., 2003), or inﬂuenza
(Berthoud et al., 2011). However, MVA based vaccines are also able
to elicit strong antibody responses (Draper et al., 2013). MVA has
been used to develop a promising antibody-inducing vaccine
against viral surface proteins, such as the haemagglutinin (HA) of
inﬂuenza virus (Kreijtz et al., 2009), or the spike glycoprotein of
SARS (Chen et al., 2005). In vaccination studies for BTV, MVA has
been very effective as a vaccine, inducing a robust VNAb response
against the expressed VP2 protein (Calvo-Pinilla et al., 2009; Jabbar
et al., 2013). Similarly, MVA expressing AHSV-VP2 has been shown
to elicit high levels of neutralizing antibodies (Castillo-Olivares
et al., 2011; Chiam et al., 2009).
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vaccination induces a highly protective humoral immune response
against AHSV (Calvo-Pinilla et al., 2014). In that study, AHSV-spe-
ciﬁc interferon-c secreting CD8+ T cells were also induced by vac-
cination with MVA-VP2, but their role in protection could not be
evaluated at that time. Previously, Pretorius et al. (2012) demon-
strated an increase of virus speciﬁc CD8+ T-cells in horses, in
response to vaccination with live attenuated AHSV. Vaccination
studies in mice using recombinant MVA expressing AHSV-4 NS1,
administered in combination with MVA-VP2, also showed speciﬁc
T-cell responses and a reduction in viraemia following heterolo-
gous challenge (de la Poza et al., 2013). In addition, a recombinant
Canarypox expressing AHSV-VP2 and VP5 was able to induce VP2-
speciﬁc CD8+ T-cell responses, alongside VNAb. This suggests cell-
mediated immunity could play a signiﬁcant role in the overall level
of protection against AHSV (El Garch et al., 2012). However, a clear
demonstration of the protective effect of this effector mechanism
of immunity, through adoptive transfer of CD8+ T-cells has not
yet been reported.
In the present study, adoptive transfer of splenocytes from
MVA-VP2 vaccinated mice, signiﬁcantly reduced the clinical score
of AHSV challenged recipient mice, and resulted in a 40% survival,
although changes in the survival rate and the reduction in viraemia
were not considered to be mathematically signiﬁcant. This sug-
gests that the role of cell-mediated immune responses is less
important than the antibody responses in the protection generated
by MVA-VP2 vaccination. In addition, it can be argued that the
marginal protection against AHSV shown by the recipients of
splenocytes could be due to AHSV-VP2-speciﬁc B cells contained
in the transferred cells. Additional adoptive transfer experiments
using cell-sorted CD8+ lymphocytes from donors before challenge
could help to elucidate the precise contribution of cell-mediated
immunity following MVA-VP2 vaccination.
In studies with the related orbivirus BTV, adoptive transfer of
CD8+ cytotoxic cells from a BTV infected sheep, partially protected
recipient sheep against infection with either homologous or heter-
ologous BTV serotypes (Jeggo et al., 1984a). In contrast, when pas-
sive transfer of antibodies from infected animals was performed,
the protection was complete against virulent virus (Jeggo et al.,
1984b). In the case of AHSV, the humoral nature of protection
against the virus has been demonstrated by the passive transfer
of a monoclonal neutralising antibody against VP2 protein in the
neonatal mouse model (Burrage et al., 1993). Passive transfer of
neutralising antibodies has also been described from AHSV vacci-
nated mares to foals via colostrum (Blackburn and Swanepoel,
1988; Crafford et al., 2013).
In the present study, consistent with previous observations, the
highly protective effect of antiserum derived from MVA-VP2 vacci-
nated mice was also demonstrated even when transferred 48 h
post-infection. When the antiserum dose was increased (Group
5), the protective effect was very close to that shown by the
actively immunized MVA-VP2 vaccinated mice. The limited clinical
signs that were still evident in mice infected 48 h before transfer,
eventually disappeared and the animals recovered completely
(Group 8). This suggests that passive immunisation with MVA-
VP2 antiserum could be used for therapeutic applications, in par-
ticular for emergency treatment of AHS in horses during the initial
stages of an outbreak, before containment measures or widespread
vaccination campaigns are initiated.
In this and previous studies it has been shown that MVA-VP2
vaccination induces high VNAb responses both in mice and horses
and is highly protective against AHSV in both experimental sys-
tems. It can be concluded that protection is mainly associated
with antibodies, since passive transfer of immune serum
from MVA-VP2 vaccinated mice is sufﬁcient to provide clinical
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